An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172.

Trial Profile

An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Feb 2016 According to ClinicalTrials.gov record,primary end points has been revised also study design changed from randomised to non-randomised.
    • 30 Sep 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top